.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after an average consequence of 11 months, people along with metastatic stomach tumors who acquired biomarker-matched therapies based upon spreading lump DNA profiling showed a more significant clinical advantage than those receiving unparalleled therapy.